|
|
| |
|
|
| |
Definition
« The pharmacotherapeutic follow-up dossier is constituted by collecting Pharmaceutical Opinions pertaining to a patient and with his approval. It includes information from administrative, pharmaceutical, medical sources (information sent by the physician dealing with a particular drug delivery or terrain) and biological sources (relevant analysis results) that are of use for delivery ».
The pharmacist cannot follow a patient whose pathological situation is chronic and/or complex without the support of a certain number of pathological, biometric, biological and psychosocial indicators.
This information is gathered as products or devices are dispensed, depending on the quality of the relation established with the patient, physician(s) and other health care professional who may be involved. It is obtained from varied sources, e.g. administrative, pharmaceutical, medical, or by simply questioning the patient, is gathered during the Pharmaceutical Opinion process and then recorded.
The systematic collection of these data with reference to a specific patient is organized to constitute a « Pharmacotherapeutic follow-up dossier » for the patient's benefit.
This process enables the pharmacist to automatically have available an increasingly higher level of information in the course of time. He may thus have a better understanding of the patient at the time of delivery, in the framework of his competence and legal limits as a health care professional.
How does a pharmacotherapeutic follow-up dossier function ?
Every person entering a community pharmacy does so at varying frequencies that depend primarily on the nature of the disorder to treat.
Although the principle of the concept of the Pharmaceutical Opinion presupposes that is it conducted systematically, the type of questions to which it gives rise depends on the disease. It is not difficult to imagine that a patient with non-insulin-dependent diabetes generates questions more systematically than in the case of seasonal problems, because of the chronic nature of the disease.
This is why the specifications of the Pharmaceutical Opinion contain the requirement for the priority use of data whose monitoring constitutes the surveillance of risk factors for a given disease.
What are the consequences of using a pharmacotherapeutic follow-up dossier ?
At the professional level, the aim of rules setting down the specifications is to ensure a common structure and vocabulary. This ensures understanding by health care professionals and also the use of drug interaction databases for products, and those for products with regard to a therapeutic profile.
The collation of Pharmaceutical Opinions by the pharmacist enables him to :
 refine
his analyses as products are delivered,
prepare
pharmacotherapeutic follow-up and ensure pharmaceutical care,
clarify
his responsibilities and initiatives in the therapeutic chain,
plan
on networking.
For the patient, the preparation of a pharmacotherapeutic follow-up dossier ensures that pharmaceutical surveillance will be supported and rigorous, conducted in cooperation with other health care professionals and be protected by professional secrecy. Data input with the approval of the patient ensures his or her cooperation and involvement that lead to better compliance with the treatment.
|
|
Pharmaceutical
Opinion and the pharmacist
